{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:28:29Z","timestamp":1787315309667,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Adult-onset Still\u2019s disease is a systemic inflammatory disease characterized by high spiking fever, arthritis, evanescent skin rash, leukocytosis, and hyperferritinemia. The pathogenesis of adult-onset Still\u2019s disease has not been fully understood yet; however, multiple proinflammatory cytokines, such as IL-1\u03b2 and IL-6, play important roles in the development of adult-onset Still\u2019s disease. IL-6 is a multifunctional cytokine that accelerates the differentiation of macrophages and cytotoxic T-cells and chemotaxis of neutrophils and macrophages. Serum concentrations of IL-6 well correlate with disease activity of adult-onset Still\u2019s disease, and blockade of IL-6 has been proven to be effective in active adult-onset Still\u2019s disease. This review will focus on the recent understanding of the role of proinflammatory cytokines of adult-onset Still\u2019s disease and the efficacy of IL-6 inhibitors for the treatment of adult-onset Still\u2019s disease.<\/jats:p>","DOI":"10.1093\/mr\/roab004","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T09:03:31Z","timestamp":1639213411000},"page":"12-15","source":"Crossref","is-referenced-by-count":13,"title":["Interluekin-6 inhibitors for the treatment of adult-onset Still\u2019s disease"],"prefix":"10.1093","volume":"32","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2022010905373634700_R1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022010905373634700_R2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","article-title":"Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart","volume":"61","author":"Jamilloux","year":"2015","journal-title":"Immunol Res"},{"key":"2022010905373634700_R3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07853890.2014.971052","article-title":"Adult-onset Still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options","volume":"47","author":"Kadavath","year":"2015","journal-title":"Ann Med"},{"key":"2022010905373634700_R4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022010905373634700_R5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still\u2019s disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2022010905373634700_R6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/14397595.2014.973659","article-title":"The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: a retrospective, single-center study","volume":"25","author":"Nishina","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022010905373634700_R7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/ard.54.7.587","article-title":"Epidemiology of adult Still\u2019s disease: estimate of the incidence by a retrospective study in west France","volume":"54","author":"Magadur-oly","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2022010905373634700_R8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","article-title":"Estimated prevalence and incidence of adult Still\u2019s disease: findings by a nationwide epidemiological survey in Japan","volume":"7","author":"Wakai","year":"1997","journal-title":"J Epidemiol"},{"key":"2022010905373634700_R9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","article-title":"Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan","volume":"25","author":"Asanuma","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022010905373634700_R10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009740510026616","article-title":"Epidemiology and outcome of adult-onset Still\u2019s disease in Northern Norway","volume":"35","author":"Evensen","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"2022010905373634700_R11","first-page":"1","article-title":"Clinical features of elderly-onset adult-onset Still\u2019s disease","volume":"13","author":"Maruyama","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022010905373634700_R12","first-page":"665","article-title":"Adult Still\u2019s disease\u2014recognition of a clinical syndrome and recent experience","volume":"142","author":"Larson","year":"1985","journal-title":"West J Med"},{"key":"2022010905373634700_R13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2005.042143","article-title":"Diagnosis and management of adult onset Still\u2019s disease","volume":"65","author":"Eft Himiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022010905373634700_R14","first-page":"23","article-title":"Adult-onset Still\u2019s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse","volume":"37 Suppl 121","author":"Takakuwa","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022010905373634700_R15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.md.0000188009.47085.76","article-title":"Adult-onset Still disease as the cause of fever of unknown origin","volume":"84","author":"Crispin","year":"2005","journal-title":"Medicine"},{"key":"2022010905373634700_R16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1872-034X.2010.00707.x","article-title":"Clinical features of liver dysfunction in collagen diseases","volume":"40","author":"Takahashi","year":"2010","journal-title":"Hepatol Res"},{"key":"2022010905373634700_R17","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R18","first-page":"322","article-title":"Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease","volume":"28","author":"Fautrel","year":"2001","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/path.4812","article-title":"The burgeoning field of innate immune-mediated disease and autoinflammation","volume":"241","author":"Peckham","year":"2017","journal-title":"J Pathol"},{"key":"2022010905373634700_R20","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2022010905373634700_R22","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2003.016428","article-title":"Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis","volume":"63","author":"Rooney","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2022010905373634700_R23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022010905373634700_R24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","article-title":"Cytokine and immunogenetic profiles in Japanese patients with adult Still\u2019s disease. Association with chronic articular disease","volume":"40","author":"Fujii","year":"2001","journal-title":"Rheumatology"},{"key":"2022010905373634700_R25","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R26","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00296-010-1631-y","article-title":"Treatment of refractory adult-onset Still\u2019s disease with tocilizumab: report of two cases and review of the literature","volume":"31","author":"Thonhofer","year":"2011","journal-title":"Rheumatol Int"},{"key":"2022010905373634700_R27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","article-title":"Tocilizumab in refractory adult Still\u2019s disease","volume":"63","author":"Pu\u00e9chal","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022010905373634700_R28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series","volume":"33","author":"Cipriani","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2022010905373634700_R29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.semarthrit.2010.05.003","article-title":"Tocilizumab in refractory adult-onset Still\u2019s disease with aseptic meningitis\u2014efficacy of interleukin-6 blockade and review of the literature","volume":"40","author":"Sabnis","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2022010905373634700_R30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/s10165-011-0569-6","article-title":"Therapeutic response of patients with adult Still\u2019s disease to biologic agents: multicenter results in Japan","volume":"22","author":"Suematsu","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2022010905373634700_R31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022010905373634700_R32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022010905373634700_R33","first-page":"1","article-title":"Effectiveness of subcutaneous tocilizumab in refractory adult Still\u2019s disease: report of three cases and a review of the literature","volume":"9","author":"Torigoe","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2022010905373634700_R34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00296-020-04622-4","article-title":"Treatment of refractory adult onset Still\u2019s disease with tocilizumab-a single centre experience and literature review","volume":"40","author":"Reihl Crnogaj","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022010905373634700_R35","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/rheumatology\/kez154","article-title":"Efficacy of sarilumab in adult-onset Still\u2019s disease as a corticosteroid-sparing agent","volume":"58","author":"Simeni Njonnou","year":"2019","journal-title":"Rheumatology"},{"key":"2022010905373634700_R36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","volume":"42","author":"Yokota","year":"2015","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R37","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","article-title":"Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan","volume":"75","author":"Yokota","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022010905373634700_R38","doi-asserted-by":"crossref","DOI":"10.1007\/s13554-012-0001-6","article-title":"Treatment of systemic juvenile idiopathic arthritis with tocilizumab \u2013 the role of anti-interleukin-6 therapy after a decade of treatment","volume":"2","author":"Reiff","year":"2012","journal-title":"Biol Ther"},{"key":"2022010905373634700_R39","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022010905373634700_R40","doi-asserted-by":"crossref","DOI":"10.1080\/24725625.2020.1818961","article-title":"Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still\u2019s disease with a previous successful tocilizumab treatment","author":"Naniwa","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"2022010905373634700_R41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/24725625.2020.1741073","article-title":"Successful use of short-term add-on tocilizumab for refractory adult-onset still\u2019s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide","volume":"4","author":"Ohmura","year":"2020","journal-title":"Mod Rheumatol Case Rep"},{"key":"2022010905373634700_R42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/adc.85.5.421","article-title":"Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders","volume":"85","author":"Sawhney","year":"2001","journal-title":"Arch Dis Child"},{"key":"2022010905373634700_R43","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"2022010905373634700_R44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3899\/jrheum.100996","article-title":"An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"38","author":"Dav\u00ec","year":"2011","journal-title":"J Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab004\/41746013\/roab004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/12\/42083337\/roab004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/12\/42083337\/roab004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T21:47:23Z","timestamp":1642542443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/12-15\/6348533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,12]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab004","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,12]]}}}